509 related articles for article (PubMed ID: 10550166)
21. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.
Smith TJ; Temin S; Alesi ER; Abernethy AP; Balboni TA; Basch EM; Ferrell BR; Loscalzo M; Meier DE; Paice JA; Peppercorn JM; Somerfield M; Stovall E; Von Roenn JH
J Clin Oncol; 2012 Mar; 30(8):880-7. PubMed ID: 22312101
[TBL] [Abstract][Full Text] [Related]
22. Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.
Alvarez Secord A; Bae-Jump V; Havrilesky LJ; Calingaert B; Clarke-Pearson DL; Soper JT; Gehrig PA
Int J Gynecol Cancer; 2009 Apr; 19(3):447-54. PubMed ID: 19407573
[TBL] [Abstract][Full Text] [Related]
23. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
24. Innovations in American Society of Clinical Oncology Practice Guideline Development.
Somerfield MR; Bohlke K; Browman GP; Denduluri N; Einhaus K; Hayes DF; Khorana AA; Miller RS; Mohile SG; Oliver TK; Ortiz E; Lyman GH
J Clin Oncol; 2016 Sep; 34(26):3213-20. PubMed ID: 27382097
[TBL] [Abstract][Full Text] [Related]
25. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ
J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline.
Mousavi S; Dadpoor M; Ashrafi F
Int J Hematol Oncol Stem Cell Res; 2016 Apr; 10(2):85-91. PubMed ID: 27252808
[TBL] [Abstract][Full Text] [Related]
27. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
[TBL] [Abstract][Full Text] [Related]
28. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N; Tanaka S; Takahata T; Sato A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
[TBL] [Abstract][Full Text] [Related]
29. Real-World Conundrums and Biases in the Use of White Cell Growth Factors.
Smith TJ; Hillner BE
Am Soc Clin Oncol Educ Book; 2016; 35():e524-7. PubMed ID: 27249762
[TBL] [Abstract][Full Text] [Related]
30. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
32. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
Schneider BJ; Daly ME; Kennedy EB; Antonoff MB; Broderick S; Feldman J; Jolly S; Meyers B; Rocco G; Rusthoven C; Slotman BJ; Sterman DH; Stiles BM
J Clin Oncol; 2018 Mar; 36(7):710-719. PubMed ID: 29106810
[TBL] [Abstract][Full Text] [Related]
34. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
35. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Gralow J; Ozols RF; Bajorin DF; Cheson BD; Sandler HM; Winer EP; Bonner J; Demetri GD; Curran W; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Ramsey S; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Davidson NE; Schilsky RL; Lichter AS;
J Clin Oncol; 2008 Jan; 26(2):313-25. PubMed ID: 18086794
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
Djulbegovic B
Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
[TBL] [Abstract][Full Text] [Related]
37. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty.
Wasif N; Ye X; Giuliano AE
Ann Surg Oncol; 2009 Sep; 16(9):2442-9. PubMed ID: 19506955
[TBL] [Abstract][Full Text] [Related]
38. ASCO's International programs and how you can become involved.
El Saghir NS; Assi HA; Pyle D
Am Soc Clin Oncol Educ Book; 2013; ():405-10. PubMed ID: 23714561
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
Chan KK; Siu E; Krahn MD; Imrie K; Alibhai SM
J Clin Oncol; 2012 Apr; 30(10):1064-71. PubMed ID: 22393098
[TBL] [Abstract][Full Text] [Related]
40. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Al-Kali A; Ozer H
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]